New model could personalize statin muscle-risk counseling

Clinical takeaway: This large study reinforces that serious muscle disorders are uncommon for most statin-eligible adults, adding evidence clinicians can use to put severe muscle-risk concerns in context. The model also offers a potential framework for future counseling by pairing muscle-risk estimates with cardiovascular benefit discussions.

Muscle symptoms often lead patients to avoid, delay, or stop statins. A new clinical prediction model may help clinicians discuss serious muscle risks more clearly with patients considering or already taking statins, according to a large retrospective cohort study from England.

The model focused on clinically consequential events — muscle disorders associated with hospitalization or death, such as rhabdomyolysis — rather than mild muscle symptoms, which are common in practice and often not caused by statins.

Researchers developed the model using primary care electronic health record data from more than 1.7 million adults potentially eligible for statin treatment, then tested it in a separate validation cohort of nearly 3.9 million adults.

Serious muscle disorders were rare. In the validation cohort, cumulative incidence was 0.07% at one year, 0.24% at five years, and 0.44% at ten years. Nearly all patients had low predicted risk, with 99.6% of the validation cohort estimated to have a ten-year risk below 10%.

The model estimated risk using factors commonly available in primary care records, including current or recent statin use, prior muscle problems, vitamin D deficiency, use of other potentially myotoxic drugs, demographics, comorbidities, and other medication history. The strongest predictors of higher risk were prior muscle problems, vitamin D deficiency, other myotoxic medications, and statin use.

The tool may help clinicians identify the smaller group of patients who warrant closer review before or during statin therapy, such as those with prior muscle problems, interacting or myotoxic medications, or other risk factors. In those patients, the model could support more targeted counseling, medication review, symptom monitoring, or consideration of alternative lipid-lowering therapy when appropriate.

The authors emphasized that the tool is not intended to replace cardiovascular risk assessment. Instead, it could be used alongside cardiovascular risk calculators to make benefit-harm discussions more concrete and support shared decision-making.

The study supports a more balanced approach to statin counseling: serious muscle harms can occur, but they appear uncommon for most statin-eligible adults. Pairing cardiovascular benefit estimates with serious muscle risk estimates may help reduce inappropriate statin avoidance or discontinuation while still identifying patients who need extra caution.

“Our model provides a reliable prediction for personalized risk of serious muscle disorders in individuals eligible for statin treatment, which could support well informed shared treatment decision making and help improve unsatisfactory statin uptake and adherence,” the authors concluded.

Source: Cai T, et al. 2026 June 25. Lancet Digit Health. Predicting the risk of serious muscle disorders in individuals eligible for statin treatment in England: derivation and validation of a clinical prediction model